Jianhong Fu
Overview
Explore the profile of Jianhong Fu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu W, Zhou F, Song Y, Zhou S, Du F, Zhu Q, et al.
Transpl Immunol
. 2024 Dec;
88:102162.
PMID: 39719162
Hemophagocytic lymphohistiocytosis (HLH) is a severe disorder with poor clinical outcomes. Use of emapalumab, an IFN-γ inhibitor, enables primary HLH control in over 85 % of affected children. However, data...
2.
Lu Y, You T, Ma Q, Wang W, Qi J, Yang P, et al.
Cancer Med
. 2024 Jul;
13(13):e7409.
PMID: 38967515
Aim: This study aimed to explore the association between patient-reported items at different time points after hematopoietic stem cell transplantation (HSCT) and long-term survival. Methods: We conducted a study with...
3.
Jiang P, Yang P, Wang W, Cao J, Chen W, Fu J, et al.
Asia Pac J Oncol Nurs
. 2024 Mar;
11(3):100368.
PMID: 38426045
Effectively addressing the challenges posed by relapsed and refractory diffuse large B-cell lymphoma, particularly when employing autologous hematopoietic stem cell transplantation and CAR-T therapy, requires a comprehensive approach to treatment...
4.
Song Y, Li W, Wu D, He X, Fu J
J Clin Immunol
. 2024 Feb;
44(3):70.
PMID: 38400989
No abstract available.
5.
Liang P, Xie Y, Liu Z, Wang D, Li Q, Lu Y, et al.
Br J Haematol
. 2024 Jan;
204(4):1219-1226.
PMID: 38180132
Venetoclax (VEN) in combination with hypomethylating agents (HMAs) is considered the standard of treatment for individuals with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. We...
6.
Xie J, Bao X, Xue S, Shen H, Cen J, Yao L, et al.
Blood
. 2023 Jul;
142(15):1323-1327.
PMID: 37478399
No abstract available.
7.
Jiang D, Huang H, Qin H, Tang K, Shi X, Zhu T, et al.
Nat Commun
. 2023 Jun;
14(1):3642.
PMID: 37339964
BCMA-targeting chimeric antigen receptor (CAR) T cell therapy demonstrates impressive clinical response in multiple myeloma (MM). However, some patients with BCMA-deficient tumours cannot benefit from this therapy, and others can...
8.
Peng C, Deng Z, Fu J, Cao Q, Zhang J, Li Q, et al.
ACS Omega
. 2023 Mar;
8(9):8846-8864.
PMID: 36910932
In petroleum drilling, carbonate formations characterized by natural fractures can result in troublesome gas-liquid gravity displacement, which refers to the phenomenon that the drilling mud leakage and gas kick are...
9.
Tong X, Ru Y, Fu J, Wang Y, Zhu J, Ding Y, et al.
Front Immunol
. 2022 Jul;
13:904693.
PMID: 35784355
Natural killer (NK) cells have been demonstrated as a promising cellular therapy as they exert potent anti-tumor immune responses. However, applications of NK cells to tumor immunotherapy, especially in the...
10.
Xu Y, Gu C, Wang R, Qi J, Wang J, Jiang T, et al.
J Clin Lab Anal
. 2022 Jun;
36(7):e24547.
PMID: 35689538
Introduction: Thrombotic thrombocytopenic purpura (TTP) is becoming a curable disease with the introduction of therapeutic plasma exchange (TPE). However, cardiovascular complications remain essential causes of mortality in patients with refractory...